Yoshiyuki Yoshinaka

Summary

Affiliation: Tokyo Medical and Dental University
Country: Japan

Publications

  1. ncbi Pycnogenol, a procyanidin-rich extract from French maritime pine, inhibits intracellular replication of HIV-1 as well as its binding to host cells
    Wu Yu Feng
    Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, Tokyo 113 5819, Japan
    Jpn J Infect Dis 61:279-85. 2008
  2. ncbi Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton
    Yu Zhong
    Department of Molecular Virology, Bio-Response, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Tokyo 113-8519, Japan
    Antiviral Res 66:119-28. 2005
  3. ncbi Utilization of host SR protein kinases and RNA-splicing machinery during viral replication
    Takeshi Fukuhara
    Laboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
    Proc Natl Acad Sci U S A 103:11329-33. 2006
  4. ncbi HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
    Norio Yamamoto
    Department of Molecular Virology, Bio Response, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Biochem Biophys Res Commun 318:719-25. 2004
  5. ncbi The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
    Vaccine 23:2269-72. 2005
  6. ncbi Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan
    Adv Exp Med Biol 581:561-6. 2006

Collaborators

Detail Information

Publications6

  1. ncbi Pycnogenol, a procyanidin-rich extract from French maritime pine, inhibits intracellular replication of HIV-1 as well as its binding to host cells
    Wu Yu Feng
    Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, Tokyo 113 5819, Japan
    Jpn J Infect Dis 61:279-85. 2008
    ..Inhibition of HIV-1 replication associated with induced expression of Mn-SOD in cells treated with PYC suggests the potential of this natural antioxidant inducer as a new anti-HIV-1 agent...
  2. ncbi Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton
    Yu Zhong
    Department of Molecular Virology, Bio-Response, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Tokyo 113-8519, Japan
    Antiviral Res 66:119-28. 2005
    ..The inhibitory activity of the extract was also not reduced after pronase digestion. The active factor in the extract is likely to be a novel compound(s) having a polyanionic substructure and a molecular weight of 10,000-50,000...
  3. ncbi Utilization of host SR protein kinases and RNA-splicing machinery during viral replication
    Takeshi Fukuhara
    Laboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
    Proc Natl Acad Sci U S A 103:11329-33. 2006
    ..Thus, we show that SRPK, a well known kinase in the cellular RNA-processing machinery, is used by at least some viruses for propagation and hence suggest that SRPIN340 or its derivatives may be useful for curbing viral diseases...
  4. ncbi HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
    Norio Yamamoto
    Department of Molecular Virology, Bio Response, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Biochem Biophys Res Commun 318:719-25. 2004
    ..Our results suggest that nelfinavir should be examined clinically for the treatment of SARS and has potential as a good lead compound for designing anti-SARS drugs...
  5. ncbi The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
    Vaccine 23:2269-72. 2005
    ..As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines...
  6. ncbi Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan
    Adv Exp Med Biol 581:561-6. 2006
    ..These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines...